

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

761195Orig1s000

Trade Name: Vyvgart

Generic or Proper Name: efgartigimod alfa-fcab

Sponsor: argenx BV

Approval Date: December 17, 2021

Indication: For the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

CENTER FOR DRUG EVALUATION AND RESEARCH

761195Orig1s000

CONTENTS

| |
|---|
| Reviews / Information Included in this NDA Review. |
|---|

| | |
|--|----------|
| Approval Letter | X |
| Other Action Letters | |
| Labeling | X |
| REMS | |
| Officer/Employee List | X |
| Integrated Review(s) | X |
| Product Quality Review(s) | X |
| Other Reviews | X |
| Risk Assessment and Risk Mitigation Review(s) | X |
| Proprietary Name Review(s) | X |
| Administrative/Correspondence Document(s) | X |

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761195Orig1s000

APPROVAL LETTER



BLA 761195

GENERAL ADVICE

argenx BV
Attention: Purve Patel, RPh
Head of US Regulatory Affairs
33 Arch Street, 32nd Floor
Boston, MA 02110

Dear Ms. Patel:

Please refer to your Biologics License Application (BLA) under section 351(a) of the Public Health Service Act for Vyvgart (efgartigimod alfa-fcab) injection for intravenous use.

We also refer to our approval letter dated December 17, 2021, wherein the year listed for the application date and receipt date was incorrectly cited as *2021*. The correct application date and receipt date is *December 17, 2020*.

| Approval Letter Section | Incorrect Language | Correct Language |
|---------------------------|--|--|
| First page, 1st paragraph | Please refer to your biologics license application (BLA) dated <i>December 17, 2021</i> , received <i>December 17, 2021</i> , and your amendments, submitted under section 351(a) of the Public Health Service Act for Vyvgart (efgartigimod alfa-fcab) injection for intravenous use. | Please refer to your biologics license application (BLA) dated <i>December 17, 2020</i> , received <i>December 17, 2020</i> , and your amendments, submitted under section 351(a) of the Public Health Service Act for Vyvgart (efgartigimod alfa-fcab) injection for intravenous use. |

This General Advice letter acknowledges the error described above and incorporates the correction of the error. The effective approval date will remain December 17, 2021, the date of the original approval letter.

If you have any questions, contact Michael Matthews, Regulatory Project Manager, via email at Michael.Matthews@fda.hhs.gov or via telephone at (301) 796-3047.

Sincerely,

{See appended electronic signature page}

Teresa Buracchio, MD
Director (Acting)
Division of Neurology 1
Office of Neuroscience
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TERESA J BURACCHIO
01/05/2022 04:42:23 PM

BLA 761195

BLA APPROVAL

argenx BV
Attention: Purve Patel, RPh
Head of US Regulatory Affairs
33 Arch Street, 32nd Floor
Boston, MA 02110

Dear Ms. Patel:

Please refer to your biologics license application (BLA) dated December 17, 2021, received December 17, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for Vyvgart (efgartigimod alfa-fcab) injection for intravenous use.

LICENSING

We are issuing Department of Health and Human Services U.S. License No. 2217 to argenx BV, Zwijnaarde, Belgium, under the provisions of section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product Vyvgart (efgartigimod alfa-fcab). Vyvgart is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture Efgartigimod alfa-fcab drug substance at (b) (4). The final drug product will be manufactured, filled, labeled, and packaged at (b) (4). Secondary packaging will take place at (b) (4).

You may label your product with the proprietary name, Vyvgart, and market it as a 400 mg/20 mL single-dose vial, injection.

DATING PERIOD

The dating period for Vyvgart shall be 36 months from the date of manufacture when stored at $5 \pm 3^{\circ}\text{C}$. The date of manufacture shall be defined as the date of final sterile

filtration of the (b) (4) drug product. The dating period for your (b) (4) drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4).

Results of ongoing stability should be submitted throughout the dating period, as they become available, including the results of stability studies from the PPQ production lots.

We have approved the stability protocols in your license application for the purpose of extending the expiration dating period of your drug substance and drug product under 21 CFR 601.12.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Vyvgart to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Vyvgart, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

At the end of the Prescribing Information, the placeholder (i.e., XXXX) for the license number has been revised to the assigned number noted above (i.e., 2217).

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.²

The SPL will be accessible via publicly available labeling repositories.

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted October 20, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761195.**” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for Vyvgart was not referred to an FDA advisory committee because the safety profile of Vyvgart is acceptable for the intended population, the clinical trial design is acceptable, and the efficacy findings were clear.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of adverse maternal, fetal, and infant outcomes resulting from exposure to Vyvgart during pregnancy.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following study:

- 4202-1 Conduct a worldwide descriptive study that collects prospective and retrospective data in women exposed to Vyvgart (efgartigimod) during pregnancy and/or lactation to assess risk of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant. Infant outcomes will be assessed through at least the first year of life. The minimum number of patients will be specified in the protocol.

The timetable you submitted on November 12, 2021, states that you will conduct this study according to the following schedule:

Draft Protocol Submission: 03/2022

Final Protocol Submission: 01/2023

Interim Reports: 03/2024

03/2025

03/2026

03/2027

03/2028

03/2029

03/2030

03/2031

03/2032

03/2033

Study Completion: 01/2033

Final Report Submission: 12/2033

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.³

Submit clinical protocol(s) to your IND 132953, with a cross-reference letter to this BLA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your BLA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).

Submission of the protocol(s) for required postmarketing observational studies to your IND is for purposes of administrative tracking only. These studies do not constitute

³ See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019).

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

U.S. Food and Drug Administration

Silver Spring, MD 20993

www.fda.gov

clinical investigations pursuant to 21 CFR 312.3(b) and therefore are not subject to the IND requirements under 21 CFR part 312.

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 601.70 requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 601.70 to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 601. We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

REQUESTED PHARMACOVIGILANCE

We request that you perform postmarketing surveillance for serious events related to malignancy, reactivation of hepatitis B or of latent tuberculosis, and infection including opportunistic infection. Include analyses of individual events as well as comprehensive summaries and analyses of these events, including incidence, quarterly as part of your required postmarketing safety reports [e.g., periodic safety update reports (PSURs)]. Include analyses of the events by age and sex. In the analysis of each case, provide an assessment of causality, with documentation of risk factors and results of all assessments that support the diagnosis or the causality, including IgG levels if available, along with extent of exposure to Vyvgart and most recent exposure to Vyvgart, concomitant therapies, treatment given for the event, and outcome.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.⁴

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication

⁴ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.
U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

[21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁵ Information and Instructions for completing the form can be found at FDA.gov.⁶

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80).

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

POST APPROVAL FEEDBACK MEETING

New biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁶ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

If you have any questions, contact Michael Matthews, Regulatory Project Manager, at Michael.Matthews@fda.hhs.gov or at (301) 796-3047.

Sincerely,

{See appended electronic signature page}

Billy Dunn, MD
Director
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILLIAM H Dunn
12/17/2021 02:54:11 PM